General Electric Medical Systems clears EU hurdle on Instrumentarium deal
This article was originally published in Clinica
Executive Summary
Constructive dialogue between General Electric Medical Systems (GEMS), its $2.2bn medical imaging take-over target Instrumentarium and the European Commission in recent weeks has finally yielded positive results. This week, the Commission finally issued its approval of the merger of the two companies - subject to certain conditions. The major hurdle now remaining is clearance by the US Department of Justice (DoJ).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.